See more : Arian Resources Corp. (GNHRF) Income Statement Analysis – Financial Results
Complete financial analysis of JUPITER NEUROSCIENCES, INC. (JUNS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of JUPITER NEUROSCIENCES, INC., a leading company in the Biotechnology industry within the Healthcare sector.
- DriveItAway Inc. (CLCN) Income Statement Analysis – Financial Results
- Cygnus Oil & Gas Corp. (CYNS) Income Statement Analysis – Financial Results
- Inflame Appliances Limited (INFLAME.BO) Income Statement Analysis – Financial Results
- Orchid Ventures, Inc. (ORCD.CN) Income Statement Analysis – Financial Results
- KU Holdings Co., Ltd. (9856.T) Income Statement Analysis – Financial Results
JUPITER NEUROSCIENCES, INC. (JUNS)
About JUPITER NEUROSCIENCES, INC.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 233.28K | 638.04K | 1.13M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 233.28K | 638.04K | 1.13M | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 954.79K | 942.81K | 1.45M | 1.64M | 685.74K |
| General & Administrative | 2.92M | 2.72M | 3.10M | 1.34M | 1.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.92M | 2.72M | 3.10M | 1.34M | 1.49M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.87M | 3.67M | 4.55M | 2.98M | 2.18M |
| Cost & Expenses | 3.87M | 3.67M | 4.55M | 2.98M | 2.18M |
| Interest Income | 482.00 | 617.00 | 132.00 | 38.00 | 4.00 |
| Interest Expense | 218.71K | 740.85K | 113.99K | 13.54K | 317.10K |
| Depreciation & Amortization | -694.21K | -784.28K | -179.17K | 210.43K | -552.96K |
| EBITDA | -4.56M | -4.22M | -4.09M | -1.64M | -2.73M |
| EBITDA Ratio | 0.00% | -1,807.57% | -640.44% | -145.72% | 0.00% |
| Operating Income | -3.87M | -3.43M | -3.91M | -1.85M | -2.18M |
| Operating Income Ratio | 0.00% | -1,471.38% | -612.36% | -164.41% | 0.00% |
| Total Other Income/Expenses | -912.92K | -1.53M | -293.16K | 196.90K | -870.06K |
| Income Before Tax | -4.78M | -4.96M | -4.20M | -1.65M | -3.05M |
| Income Before Tax Ratio | 0.00% | -2,125.15% | -658.31% | -146.92% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 179.17K | 0.00 | 0.00 |
| Net Income | -4.78M | -4.96M | -4.38M | -1.65M | -3.05M |
| Net Income Ratio | 0.00% | -2,125.15% | -686.39% | -146.92% | 0.00% |
| EPS | -0.15 | -0.15 | -0.44 | -0.19 | -0.35 |
| EPS Diluted | -0.15 | -0.15 | -0.44 | -0.19 | -0.35 |
| Weighted Avg Shares Out | 32.88M | 32.88M | 9.49M | 8.74M | 8.74M |
| Weighted Avg Shares Out (Dil) | 32.88M | 32.88M | 9.49M | 8.74M | 8.74M |
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Source: https://incomestatements.info
Category: Stock Reports